文献速递肿瘤 PET/CT核素与放射性配体治疗

雄激素阻断对PSMA表达的快速调节:激素敏感与去势抵抗前列腺癌的系列68Ga-PSMA-11 PET研究

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.
PubMed 文献 · J Nucl Med · 2018-12-14

该前瞻性研究对8例激素敏感性转移性前列腺癌(启动LHRH±比卡鲁胺)和7例去势抵抗性前列腺癌(启动恩杂鲁胺或阿比特龙)患者,在基线及第9、18、28天行系列68Ga-PSMA-11 PET。激素敏感组第9天SUVmax中位下降30%,去势抵抗组第9天SUVmax中位升高45%,提示雄激素阻断后PSMA PET反应呈快速双向性。

要点

  • 激素敏感组雄激素阻断后第9天SUVmax中位下降30%,总肿瘤体积减少74.5%。
  • 去势抵抗组第9天SUVmax和SUVmean均较基线升高,至第28天达平台。
  • PSMA PET反应因激素敏感或去势抵抗表型而异,影响PSMA靶向治疗时机与测序。

核心结论

  • 雄激素阻断后68Ga-PSMA PET呈快速双向反应,取决于前列腺癌为激素敏感还是去势抵抗表型。

研究设计与样本

  • 前瞻性研究,纳入8例可测量转移性激素敏感性前列腺癌患者(队列1,启动LHRH±比卡鲁胺)和7例去势抵抗性前列腺癌患者(队列2,启动恩杂鲁胺或阿比特龙)。
  • 在基线及第9、18、28天行系列68Ga-PSMA-11 PET,定量分析SUVmax、SUVmean和总肿瘤体积。

主要发现

  • 队列1第9天SUVmax中位下降30%(IQR 5-61),86.5%(6/7)患者SUVmax较基线下降(P<0.04),全部患者PSA应答(P<0.03)。
  • 队列1总肿瘤体积全部患者减少74.5%(IQR 27-97)(P<0.02);第9天后37.5%(3/8)患者SUVmax持续高或升高,62.5%(5/8)明显下降。
  • 队列2第9天PSMA SUV强度中位升高45%(IQR 12.7-66),全部患者SUVmax和SUVmean较基线升高(P<0.04),第9天升高至第28天达平台。
  • 队列2 PSA应答更延迟(-15%[IQR 70-138]),7例中2例出现PSA进展。

关键数值与推荐

  • 队列1第9天SUVmax中位下降30%(IQR 5-61),总肿瘤体积减少74.5%(IQR 27-97)。
  • 队列2第9天PSMA SUV中位升高45%(IQR 12.7-66),SUVmax和SUVmean升高P<0.04。

临床怎么用

  • 解读PSMA PET时应考虑雄激素阻断状态及启动时间,激素敏感与去势抵抗患者反应方向相反。
  • 启动雄激素阻断后早期PSMA PET反应可能影响PSMA靶向治疗的时机与测序决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) may be targeted for both diagnostic and therapeutic purposes in the management of prostate cancer (PCa). In preclinical models, androgen blockade (AB) increases expression of PSMA in both hormone-sensitive and castrate-resistant xenotypes. The aim of this study was to evaluate the effect of AB treatment on 68Ga-PSMA-11 PET imaging in hormone-naive (luteinizing hormone-releasing hormone [LHRH] ± bicalutamide) and in castrate-resistant men (enzalutamide or abiraterone) with metastatic PCa. Methods: Serial 68Ga-PSMA-11 PET was prospectively performed at baseline and on days 9, 18, and 28 in 8 men with measurable metastatic hormone-sensitive PCa commencing LHRH ± bicalutamide (cohort 1) and 7 men with castrate-resistant PCa commencing either enzalutamide or abiraterone (cohort 2). Gleason score, age, time since diagnosis, and prior treatments were documented. Testosterone and prostate-specific antigen (PSA) were measured at baseline and all imaging time points. PET/CT was quantitatively analyzed for SUVmax, SUVmean, and total tumor volume. Results: In cohort 1, a median 30% (interquartile range [IQR], 5-61) reduction in SUVmax was recorded by day 9 after AB. A reduction from baseline SUVmax occurred in 86.5% (6/7) men by day 9 (P < 0.04), with an associated PSA response in 100% men (P < 0.03). Total tumor volume reduced in all men by 74.5% (IQR, 27-97) (P < 0.02). After day 9, PSMA response heterogeneity was noted, with persistently high or increasing SUVmax in 37.5% (3/8) and marked reduction in 62.5% (5/8). In cohort 2, a median 45% (IQR, 12.7-66) increase in intensity of PSMA SUV was recorded by day 9 after AB. All men demonstrated an increase in SUVmax and SUVmean on PSMA PET compared with baseline (P < 0.04). This increase at day 9 plateaued by day 28. PSA responses were more delayed in cohort 2 (-15% [IQR, 70-138]), with 2 of 7 men demonstrating PSA progression. Conclusion: There is rapid dichotomous response on 68Ga-PSMA PET imaging to AB-dependent on the presence of a hormone-sensitive or castrate-resistant PCa phenotype. This has important implications for interpretation of PSMA PET, and in the timing and sequencing of PSMA-targeted therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Emmett L, Yin C, Crumbaker M, et al. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nucl Med. 2018. PMID: 30552200. doi:10.2967/jnumed.118.223099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。